This brand name is authorized in United Kingdom
The drug LAAGLYDA contains one active pharmaceutical ingredient (API):
|
1
Gliclazide
UNII G4PX8C4HKV - GLICLAZIDE
|
|
Gliclazide is a hypoglycaemic sulfonylurea antidiabetic active substance. Gliclazide reduces blood glucose levels by stimulating insulin secretion from the β-cells of the islets of Langerhans. |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| A10BB09 | Gliclazide | A Alimentary tract and metabolism → A10 Drugs used in diabetes → A10B Blood glucose lowering drugs, excl. insulins → A10BB Sulfonamides, urea derivatives |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: GB | Medicines & Healthcare Products Regulatory Agency | Identifier(s): 222251 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
